Preliminary clinical trials using the novel anti-MSLN CAR-T cell therapy in autologous T cells from three patients with chemotherapy-refractory metastatic ovarian cancer showed promising results, indicating its potential as an immunotherapeutic approach for advanced ovarian cancer [177]. The gene discussed is MSLN; the disease is ovarian cancer.